SCHEMBL9957351

SCHEMBL9957351

CCCN1CC(Oc2ccc(-c3c(-c4ccccc4Cl)noc3-c3ccc(OC(=O)C(F)(F)F)c(C)c3)cc2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
TP53 P04637 3/20 0.35
S1PR1 P21453 2/20 0.34
S1PR3 Q99500 2/20 0.34
DCTPP1 Q9H773 2/20 0.34
ALOX5 P09917 2/20 0.34
ALOX5AP P20292 2/20 0.34
ESR1 P03372 1/20 0.33
USP2 O75604 1/20 0.33
USP1 O94782 1/20 0.33
USP8 P40818 1/20 0.33
OTUB1 Q96FW1 1/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
SMURF2 Q9HAU4 1/20 0.33
SMURF1 Q9HCE7 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957059 0.89 MAPT (0.36) MAPTTP53DCTPP1ALOX5ALOX5AP
Trifluoroacetic Acid SCHEMBL9957346 0.88 HSP90AA1 (0.36) MAPTTP53S1PR1S1PR3DCTPP1
SCHEMBL9956825 0.85 ALOX5 (0.37) S1PR1S1PR3ALOX5ALOX5APESR1
SCHEMBL10169940 0.85 ESR1 (0.39) MAPTTP53S1PR1S1PR3DCTPP1
SCHEMBL17728333 0.83 ALOX5 (0.37) S1PR1S1PR3ALOX5ALOX5APESR1
Trifluoroacetic Acid SCHEMBL9957056 0.83 ESR1 (0.40) S1PR1S1PR3ALOX5ALOX5APESR1
SCHEMBL9956812 0.82 ESR1 (0.36) S1PR1S1PR3ALOX5ALOX5APESR1
SCHEMBL9956714 0.82 ALOX5 (0.37) S1PR1S1PR3ALOX5ALOX5APESR1
SCHEMBL9956414 0.81 ESR1 (0.46) MAPTTP53S1PR1S1PR3DCTPP1
Hydrochloric Acid SCHEMBL9955635 0.80 ESR1 (0.45) MAPTTP53S1PR1S1PR3DCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
EP-2655367-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES Merck Sharp & Dohme B.V. (NL) 2013-10-30 EP disclosed
WO-2012084711-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MSD OSS B.V. (NL) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES ESR2, ESR1, GPER1 MAPT 3866/4885TP53 284/4885S1PR1 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.